Patterns of Cancer Genetic Testing: A Randomized Survey of Oregon Clinicians

Table 5

Reasons why clinicians reported ordering specific cancer genomics tests in the past 12 months, among clinicians who ordered the genetic tests.

	Patient met practice guidelines; 𝑛  (%)^a; (95%  CI)^b	Guide future screening decisions; 𝑛  (%)^a; (95%  CI)^b	Guide prophylactic treatment decisions; 𝑛  (%)^a; (95%  CI)^b	Patient specifically requests it; 𝑛  (%)^a; (95%  CI)^b
BRCA for patients without BC^c or OC^d,e	207 (85.5%)	192 (79.7%)	192 (79.7%)	198 (81.1%)
	(80.5%–89.5%)	(74.1%–84.3%)	(74.1%–84.3%)	(75.7%–85.6%)
BRCA for patients with BC^c or OC^d,f	100 (82.0%)	91 (75.2%)	93 (76.2%)	97 (78.9%)
	(74.0%–87.9%)	(66.6%–82.2%)	(67.8%–83.0%)	(70.6%–85.3%)
Lynch syndrome testing^g for patients w/o CRC^h,i	72 (63.7%)	69 (60.5%)	68 (58.6%)	65 (57.0%)
	(54.3%–72.2%)	(51.2%–69.2%)	(49.3%–67.3%)	(47.7%–65.9%)
Lynch syndrome testing^g for patients with CRC^h,j	50 (72.5%)	46 (67.6%)	27 (40.3%)	32 (50.0%)
	(60.5%–81.9)	(55.4%–77.9%)	(29.0%–52.7%)^k	(37.7%–62.3%)

^aThe column % reflects the percent responding within each practice category.
^bCI: confidence interval.
^cBC: breast cancer.
^dOC: ovarian cancer.
^eAmong clinicians who recommend breast and ovarian screening to patients without breast cancer.
^fAmong clinicians who treat breast and ovarian cancer.
^gSpecifically testing for mismatch repair (MMR) genes, which may include testing in MCH1, MSH2, MSH6, and PMS2 genes.
^hCRC: colorectal cancer.
ⁱAmong clinicians who recommend colorectal cancer screening to patients without colorectal cancer.
^jAmong clinicians who treat colorectal cancer.
^kFor Lynch syndrome testing for patients with cancer, the phrasing was “guide chemotherapeutic treatment decisions.”